Research and Development Daily Phase 2 Clinical Failure AbbVie/Ironwood Abandons Research and Development MD-7246

PhasePhase II Clinical Failure AbbVie/Ironwood decided to abandon IBS experimental drug development; Mersana antibody conjugate drug to show positive POC efficacy for platinum-resistant ovarian cancer; Bayer FXla inhibitors received two clinical implied licenses in China; and Boxei Squibb agreed to partner to develop innovative "synthetic lethal" precision therapies ..We focus on the latest developments in pharmaceutical research and development, to provide research and development personnel with timely and accurate information referenceOn the 27th, Ironwood released key data on randomized, double-blind, placebo-controlled phase 2 clinical NCT03931785, MD-7246 for improving abdominal pain symptoms in patients with irritable bowel syndrome (IBS-D), and AbbVie and Ironwood Pharmaceuticals decided to suspend the development of this experimental non-opioid relieverdays ago, Roche's Gene Tek announced positive results from the third phase of the archway trial, which evaluated the effects of ranibizumab PDS (Thunderball mono-glass implant) in the treatment of new vascular (wet) age-related macular degeneration, BioLineRx, a biopharmaceutical company focused on the development of oncology drugs, announced that it is evaluating the iIa phase OF COMBAT/KEYNOTE-202 study of the lead drug CXCR4 antagonist motixafortide (BL-8040) in conjunction with Keytruda and chemotherapy to treat pancreatic cancertoday, GlaxoSmithKline announced that its antibody-linked drug (ADC) belantamab mafotin, targeting B-cell mature antigens, is further demonstrating its potential in clinical trials OF DREAMM-2 and DREAMM-6 to treat patients with recurrent/incurable multiple myeloma26, Shanghai Bowei Biotech Co., Ltdregistered to launch its four-price and nine-price recombinant HPV vaccine Phase III clinical trial, to prove that HPV tetravalent, HPV nine-price vaccination in 20-45 years of Chinese female HPV 6, 11, 16, 18-type neutralanti-anti-impotence rate is not inferior to the positive control vaccine27, Mersana Therapeutics, Inc., which focuses on developing antibody-linked drugs (ADCs), announced the medium-term safety, tolerability, and efficacy of its candidate drug, XMT-1536, for extended phase I research on ovarian and non-small cell lung adenocarcinomasOn the 27th, the European Commission (EC) has approved Zeposia (ozanimod) for the treatment of active relapse-reactive multiple sclerosis (RRMS) adult patients defined by clinical or imaging characteristicsToday, the CDE website announced that Bayer's new class 1 drug BAY 2433334 tablets in China has been granted two clinical implied licenses to develop secondary prevention of stroke in patients with acute non-cardiac infarction type strokeAccording to cDE's official website, on May 27, Roche Pharmaceuticals' application for a new indication of quto-bead mono-resistant injections was accepted27, Hansen Pharmaceuticals announced that the company's subsidiary Jiangsu Howson Pharmaceutical Group Co., Ltdand Shanghai Hansen Biopharmaceutical Technology Co., Ltdindependently developed a class of new drugs "HS-10356 tablets" on May 26, 2020 approved by the National Drug Administration issued a clinical trial notice, intended to be used to treat non-alcoholic fatty hepatitis (NASH)According to the latest public ity on the CDE website, Junshi Bio's PD-1 inhibitor Treprimono (JS001) has been granted an implicit license for a new clinical trial to develop an indication that the combination of bevalzumab first-line treatment for advanced hepatocellular carcinoma27, China Biopharmaceutical announced that the Group developed the brain nerve protection agent Yida lafeng sodium chloride injection, following the earlier domestic first imitation approved for the market, just obtained the People's Republic of China's State Drug Administration issued a drug supplement application approval, approved new indications, used to inhibit amyotrophic lateral sclerosis (commonly known as "frozen", "ALS") functional disorder progress26, Zhengda Tianqing joint Ed Cheng Ningxin registration to launch AL2846 capsules joint Gisitabin treatment of advanced pancreatic cancer Phase I tolerable clinical trial27, Bai Ota announced that the company's independent research and development of BAT1308 injections by the State Drug Administration approved clinical25, the official website of the State Drug Administration showed that The injection of Melosilin sodium shubatan sodium of Columbine Pharmaceuticals, a subsidiary of Colum Pharmaceuticals, was approved for production, becoming the eighth approved generic drug in China27, Indian generic drug giant Natco Pharma in China submitted an application for the listing of imported generic drugs (class 5.2), which is the first in China reported the import of oseltamivir capsules, and the fifth in nearly six months to declare the variety of enterprisesToday, Gilead Sciences and Arcus Biosciences jointly announced that they have entered into a 10-year partnership to jointly develop and commercialize candidate drugs in the Arcus development pipeline, including innovative PD-1 inhibitors and immunocheckpoint protein TIGIT inhibitorstoday, Repare Therapeutics, inc., which is dedicated to screening "synthetic death" precision therapies using CRISPR gene editing technology, announced that it has reached a global lying collaboration with Boxei Squibb to develop innovative "synthetic death" precision therapiesA new study published in Nature Medicine recently suggests that differences in individual genes in an individual's birth genome can affect the progression of melanomaThe researchers speculate that these genetic variants may have the same effect on other types of cancer.